Rhythm Pharmaceuticals, Inc. Common Stock
RYTMRhythm Pharmaceuticals, Inc. (RYTM) is a biotechnology company focused on developing and commercializing therapeutics for rare genetic disorders of appetite regulation. The company is known for its work on treatments targeting hypothalamic obesity and rare metabolic conditions involving the regulation of hunger and energy balance.
Company News
Rhythm Pharmaceuticals reported promising early Phase 2 trial results for setmelanotide in treating Prader-Willi syndrome, with potential therapeutic benefits in reducing BMI and extreme hunger. The company plans to advance to a Phase 3 trial and has initiated a new trial arm for a MC4R agonist.
Eli Lilly and Novo Nordisk are preparing to launch oral obesity treatment pills in 2026, with pricing expected to match existing injectable drugs, despite some underwhelming clinical trial data showing modest weight loss results.
Rhythm Pharmaceuticals reported strong Q1 2025 results, with $37.7 million in net product revenue from IMCIVREE and positive data from its pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity. The company also provided updates on its pipeline and anticipated upcoming milestones.
Rhythm Pharmaceuticals announced positive topline results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity. The trial met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index (BMI) with setmelanotide compared to placebo in b...
Rhythm Pharmaceuticals and the Raymond A. Wood Foundation have announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma, a rare neuroendocrine disease. The goal is to better understand the experiences of craniopharyngioma survivors and factors that may affect fatigue, such as weight gain and daytime ...
